The present disclosure relates to compounds, which are useful for regulating the expression of apolipoproteiπ A-I (ApoA-I), and their use for the treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis.